posted on 2021-09-17, 14:36authored byTakuya Kato, Ryuhei Okada, Yuto Goto, Aki Furusawa, Fuyuki Inagaki, Hiroaki Wakiyama, Hideyuki Furumoto, Dagane Daar, Baris Turkbey, Peter L. Choyke, Hideo Takakura, Osamu Inanami, Mikako Ogawa, Hisataka Kobayashi
Near-infrared photoimmunotherapy (NIR-PIT) employs molecularly
targeted antibodies conjugated with a photoabsorbing silicon-phthalocyanine
dye derivative which binds to cancer cells. Application of NIR light
following binding of the antibody–photoabsorber conjugates
(APCs) results in ligand release on the dye, dramatic changes in solubility
of the APC–antigen complex, and rapid, irreversible cell membrane
damage of cancer cells in a highly selective manner, resulting in
a highly immunogenic cell death. Clinically, this process results
in edema after treatment mediated by reactive oxygen species (ROS).
Based on the chemical and biological mechanism of NIR-PIT cytotoxicity
and edema formation, in order to minimize acute inflammatory edema
without compromising therapeutic effects, l-sodium ascorbate
(l-NaAA) was administered to quench harmful ROS and accelerate
the ligand release reaction. l-NaAA suppressed acute edema
by reducing ROS after NIR-PIT yet did not alter the therapeutic effects.
NIR-PIT could be performed safely under existence of l-NaAA
without side effects caused by unnecessary ROS production.